

DAFTAR PUSTAKA

- [1] J. S. Brown, S. R. Amend, R. H. Austin, R. A. Gatenby, E. U. Hammarlund, and K. J. Pienta, “Updating the Definition of Cancer,” *Mol. Cancer Res.*, vol. 21, no. 11, pp. 1142–1147, Nov. 2023, doi: 10.1158/1541-7786.MCR-23-0411.
- [2] K. Noor, “The Devastating Disease Cancer- A Theoretical Study and Recent Trends: Review,” *Int. J. Adv. Res. Innov.*, vol. 9, no. 2, pp. 24–29, 2021, doi: 10.51976/ijari.922104.
- [3] X. Chen, Q. Yu, P. Li, and S. Fu, “Landscape of Carbon Ion Radiotherapy in Prostate Cancer: Clinical Application and Translational Research,” *Front. Oncol.*, vol. 11, p. 760752, Nov. 2021, doi: 10.3389/fonc.2021.760752.
- [4] F. Bray *et al.*, “Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” *CA. Cancer J. Clin.*, vol. 74, no. 3, pp. 229–263, May 2024, doi: 10.3322/caac.21834.
- [5] M. Beyzadeoglu, G. Ozyigit, and C. Ebruli, *Basic Radiation Oncology*. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. doi: 10.1007/978-3-642-11666-7.
- [6] V. Kiseleva, K. Gordon, P. Vishnyakova, E. Gantsova, A. Elchaninov, and T. Fatkhudinov, “Particle Therapy: Clinical Applications and Biological Effects,” *Life*, vol. 12, no. 12, p. 2071, Dec. 2022, doi: 10.3390/life12122071.
- [7] X. Chen, Q. Yu, P. Li, and S. Fu, “Landscape of Carbon Ion Radiotherapy in Prostate Cancer: Clinical Application and Translational Research,” *Front. Oncol.*, vol. 11, p. 760752, Nov. 2021, doi: 10.3389/fonc.2021.760752.
- [8] T. Kamada *et al.*, “Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience,” *Lancet Oncol.*, vol. 16, no. 2, pp. e93–e100, Feb. 2015, doi: 10.1016/S1470-2045(14)70412-7.
- [9] T. Ogawa *et al.*, “Overview of PHITS Ver.3.34 with particular focus on track-structure calculation,” *EPJ Nucl. Sci. Technol.*, vol. 10, p. 13, 2024, doi: 10.1051/epjn/2024012.
- [10] T. Sato *et al.*, “Recent improvements of the particle and heavy ion transport code system – PHITS version 3.33,” *J. Nucl. Sci. Technol.*, vol. 61, no. 1, pp. 127–135, Jan. 2024, doi: 10.1080/00223131.2023.2275736.
- [11] T. Furuta and T. Sato, “Medical application of particle and heavy ion transport code system PHITS,” *Radiol. Phys. Technol.*, vol. 14, no. 3, pp. 215–225, Sept. 2021, doi: 10.1007/s12194-021-00628-0.
- [12] H.-F. Huang *et al.*, “Dosimetric comparison between stereotactic body radiotherapy and carbon-ion radiation therapy for prostate cancer,” *Quant. Imaging Med. Surg.*, vol. 13, no. 10, pp. 6965–6978, Oct. 2023, doi: 10.21037/qims-23-340.
- [13] H.-B. Shin *et al.*, “Dosimetric comparison of robust angles in carbon-ion radiation therapy for prostate cancer,” *Front. Oncol.*, vol. 13, p. 1054693, Feb. 2023, doi: 10.3389/fonc.2023.1054693.
- [14] S. Russo *et al.*, “Dosimetric Impact of Inter-Fraction Anatomical Changes in Carbon Ion Boost Treatment for High-Risk Prostate Cancer (AIRC IG



- 14300),” *Front. Oncol.*, vol. 11, p. 740661, Sept. 2021, doi: 10.3389/fonc.2021.740661.
- [15] Y. Hiroshima *et al.*, “Safety and Efficacy of Carbon-Ion Radiotherapy for Elderly Patients with High-Risk Prostate Cancer,” *Cancers*, vol. 14, no. 16, p. 4015, Aug. 2022, doi: 10.3390/cancers14164015.
- [16] Y. Wakisaka *et al.*, “Treatment planning of carbon ion radiotherapy for prostate cancer based on cellular experiments with PC3 human prostate cancer cells,” *Phys. Med.*, vol. 107, p. 102537, Mar. 2023, doi: 10.1016/j.ejmp.2023.102537.
- [17] Y. Takakusagi *et al.*, “Preliminary result of carbon-ion radiotherapy using the spot scanning method for prostate cancer,” *Radiat. Oncol.*, vol. 15, no. 1, p. 127, Dec. 2020, doi: 10.1186/s13014-020-01575-7.
- [18] S. Yonai, N. Matsufuji, and K. Akahane, “Monte Carlo study of out-of-field exposure in carbon-ion radiotherapy with a passive beam: Organ doses in prostate cancer treatment,” *Phys. Med.*, vol. 51, pp. 48–55, July 2018, doi: 10.1016/j.ejmp.2018.04.391.
- [19] G. S. Mahadevan, V. K. Arunachalam, S. Rajasekaran, R. Kashyap, K. Gunasekaran, and S. Thirumoorthi, “Anatomy of the Prostate Gland: Modalities and Techniques for Its Assessment,” *J. Gastrointest. Abdom. Radiol.*, vol. 07, no. 02, pp. 099–105, May 2024, doi: 10.1055/s-0044-1785197.
- [20] H. Baba *et al.*, “Tumor Location and a Tumor Volume over 2.8 cc Predict the Prognosis for Japanese Localized Prostate Cancer,” *Cancers*, vol. 14, no. 23, p. 5823, Nov. 2022, doi: 10.3390/cancers14235823.
- [21] O. Bergengren *et al.*, “2022 Update on Prostate Cancer Epidemiology and Risk Factors—A Systematic Review,” *Eur. Urol.*, vol. 84, no. 2, pp. 191–206, Aug. 2023, doi: 10.1016/j.eururo.2023.04.021.
- [22] J. Bociński *et al.*, “A case of high-grade prostate cancer with low PSA levels,” *Urol. Case Rep.*, vol. 62, p. 103161, Sept. 2025, doi: 10.1016/j.eucr.2025.103161.
- [23] N. Kobayashi *et al.*, “Colorectal Cancer Screening Outcomes of 2412 Prostate Cancer Patients Considered for Carbon Ion Radiotherapy,” *Cancers*, vol. 13, no. 17, p. 4481, Sept. 2021, doi: 10.3390/cancers13174481.
- [24] N. N. Junejo and S. S. AlKhateeb, “BRCA2 gene mutation and prostate cancer risk,” *Saudi Med. J.*, vol. 41, no. 1, pp. 9–17, Jan. 2020, doi: 10.15537/smj.2020.1.24759.
- [25] K. Kelly-Reif, S. Bertke, R. D. Daniels, D. B. Richardson, and M. K. Schubauer-Berigan, “Ionising radiation and solid cancer mortality among United States nuclear facility workers,” *Int. J. Epidemiol.*, vol. 52, no. 4, pp. 1015–1024, Aug. 2023, doi: 10.1093/ije/dyad075.
- [26] “Staging Prostate Cancer to Determine Treatment,” Affiliated Oncologists. Accessed: Sept. 03, 2025. [Online]. Available: <https://aocancer.com/education-resources/types-of-cancer/prostate-cancer/staging>
- [27] H. Sato *et al.*, “Long-term clinical outcomes after 12-fractionated carbon-ion radiotherapy for localized prostate cancer,” *Cancer Sci.*, vol. 112, no. 9, pp. 3598–3606, Sept. 2021, doi: 10.1111/cas.15019.



- [28] B. Turner and L. Drudge-Coates, "Prostate cancer: risk factors, diagnosis and management," *Cancer Nurs. Pract.*, vol. 9, no. 10, pp. 29–36, Dec. 2010, doi: 10.7748/cnp2010.12.9.10.29.c8126.
- [29] N. Tsoulfanidis and S. Landsberger, *Measurement & detection of radiation*, 4th edition. Boca Raton: CRC Press, Taylor & Francis Group, 2015.
- [30] Y. K. Lahir, "Non-ionizing Radiations and their Biochemical and Biomedical Impacts: A Review," *J. Radiat. Cancer Res.*, vol. 14, no. 2, p. 53, June 2023, doi: 10.4103/jrcr.jrcr_17_22.
- [31] A. Sarolkar, S. N. Singh, P. Bagdare, V. Bhandari, A. I. Lodi, and S. Moharir, "To evaluate volume changes on computerized tomography scan and magnetic resonance imaging-based delineation during radiotherapy treatment planning in prostate cancer," *J. Cancer Res. Ther.*, vol. 17, no. 2, pp. 379–382, Apr. 2021, doi: 10.4103/jcrt.JCRT_839_18.
- [32] W. Muhammad, A. Hussain, and M. Maqbool, "Basic Concepts in Radiation Dosimetry," in *An Introduction to Medical Physics*, M. Maqbool, Ed., in Biological and Medical Physics, Biomedical Engineering. , Cham: Springer International Publishing, 2017, pp. 9–41. doi: 10.1007/978-3-319-61540-0_2.
- [33] J. H. L. Mott and J. M. Daniel, "Interactions of Electromagnetic Radiation and Subatomic Particles with Matter – Part 2," *Clin. Oncol.*, vol. 33, no. 7, pp. 455–460, July 2021, doi: 10.1016/j.clon.2021.02.005.
- [34] J. E. Turner, *Atoms, radiation, and radiation protection*, 3rd completely rev. and enl. Ed. in Physics textbook. Weinheim: Wiley-VCH, 2007.
- [35] E. B. Podgoršak, "Interactions of Charged Particles with Matter," in *Radiation Physics for Medical Physicists*, E. B. Podgorsak, Ed., Berlin, Heidelberg: Springer, 2010, pp. 227–275. doi: 10.1007/978-3-642-00875-7_6.
- [36] S. H. Park and J. O. Kang, "Basics of particle therapy I: physics," *Radiat. Oncol. J.*, vol. 29, no. 3, p. 135, 2011, doi: 10.3857/roj.2011.29.3.135.
- [37] I. Rinaldi, A. Ferrari, O. Jäkel, A. Mairani, and K. Parodi, "Novel imaging and quality assurance techniques for ion beam therapy: a Monte Carlo study," pp. 575–580, Jan. 2010.
- [38] J. F. Ziegler, M. D. Ziegler, and J. P. Biersack, "SRIM – The stopping and range of ions in matter (2010)," *Nucl. Instrum. Methods Phys. Res. Sect. B Beam Interact. Mater. At.*, vol. 268, no. 11–12, pp. 1818–1823, June 2010, doi: 10.1016/j.nimb.2010.02.091.
- [39] W. L. Glab, K. Haris, and A. Kramida, "Revision of the ionization energy of neutral carbon," *J. Phys. Commun.*, vol. 2, no. 5, p. 055020, May 2018, doi: 10.1088/2399-6528/aac421.
- [40] H. K. Byun *et al.*, "Physical and Biological Characteristics of Particle Therapy for Oncologists," *Cancer Res. Treat.*, vol. 53, no. 3, pp. 611–620, July 2021, doi: 10.4143/crt.2021.066.
- [41] M. Endo, "Creation, evolution, and future challenges of ion beam therapy from a medical physicist's viewpoint (part 1). Introduction and Chapter 1. accelerator and beam delivery system," *Radiol. Phys. Technol.*, vol. 15, no. 4, pp. 271–290, Dec. 2022, doi: 10.1007/s12194-022-00681-3.



- [42] H. Ishikawa *et al.*, “Carbon-ion radiotherapy for urological cancers,” *Int. J. Urol.*, vol. 29, no. 10, pp. 1109–1119, Oct. 2022, doi: 10.1111/iju.14950.
- [43] P. Gerhard and M. Maier, “Heavy Ion Stripping,” *Proc. 15th Int. Conf. Heavy Ion Accel. Technol.*, vol. HIAT2022, p. 7 pages, 2.130 MB, 2022, doi: 10.18429/JACOW-HIAT2022-MO3I3.
- [44] T. Kamada, “Overview of the Heavy-Ion Medical Accelerator in Chiba (HIMAC) Practices,” in *Carbon-Ion Radiotherapy*, H. Tsujii, T. Kamada, T. Shirai, K. Noda, H. Tsuji, and K. Karasawa, Eds., Tokyo: Springer Japan, 2014, pp. 17–22. doi: 10.1007/978-4-431-54457-9_3.
- [45] G. van de Kamp, T. Heemskerck, R. Kanaar, and J. Essers, “DNA Double Strand Break Repair Pathways in Response to Different Types of Ionizing Radiation,” *Front. Genet.*, vol. 12, p. 738230, Sept. 2021, doi: 10.3389/fgene.2021.738230.
- [46] E. Choi, K. S. Chon, and M. G. Yoon, “Evaluating direct and indirect effects of low-energy electrons using Geant4-DNA,” *Radiat. Eff. Defects Solids*, vol. 175, no. 11–12, pp. 1042–1051, Nov. 2020, doi: 10.1080/10420150.2020.1799372.
- [47] Y. Furusawa, “Heavy-Ion Radiobiology,” in *Carbon-Ion Radiotherapy: Principles, Practices, and Treatment Planning*, H. Tsujii, T. Kamada, T. Shirai, K. Noda, H. Tsuji, and K. Karasawa, Eds., Tokyo: Springer Japan, 2014, pp. 25–37. doi: 10.1007/978-4-431-54457-9_4.
- [48] W. Tinganelli and M. Durante, “Carbon Ion Radiobiology,” *Cancers*, vol. 12, no. 10, p. 3022, Oct. 2020, doi: 10.3390/cancers12103022.
- [49] S. Yonai *et al.*, “Measurement of absorbed dose, quality factor, and dose equivalent in water phantom outside of the irradiation field in passive carbon-ion and proton radiotherapies,” *Med. Phys.*, vol. 37, no. 8, pp. 4046–4055, Aug. 2010, doi: 10.1118/1.3458721.
- [50] A. Wambersie *et al.*, “Isoeffective dose: a concept for biological weighting of absorbed dose in proton and heavier-ion therapies,” *Radiat. Prot. Dosimetry*, vol. 143, no. 2–4, pp. 481–486, Feb. 2011, doi: 10.1093/rpd/ncq410.
- [51] T. Nomiya *et al.*, “Phase I/II trial of definitive carbon ion radiotherapy for prostate cancer: evaluation of shortening of treatment period to 3 weeks,” *Br. J. Cancer*, vol. 110, no. 10, pp. 2389–2395, May 2014, doi: 10.1038/bjc.2014.191.
- [52] INTERNATIONAL ATOMIC ENERGY AGENCY, *Absorbed Dose Determination in External Beam Radiotherapy*, Rev. 1. in Technical Reports Series. INTERNATIONAL ATOMIC ENERGY AGENCY, 2024. doi: 10.61092/iaea.ve7q-y94k.
- [53] S. H. Park and J. O. Kang, “Basics of particle therapy I: physics,” *Radiat. Oncol. J.*, vol. 29, no. 3, p. 135, 2011, doi: 10.3857/roj.2011.29.3.135.
- [54] K. Noda, “Advancement of heavy-ion therapy with HIMAC,” in *Mini-Micro- Nano Dosimetry and Innovative Technologies in Radiation Oncology, 2020. Program and Abstracts*, 2020, pp. 59–59. Accessed: Sept. 15, 2025. [Online]. Available: <https://inis.iaea.org/records/garxw-hw275>



- [55] M. Muramatsu *et al.*, “Present Status of HIMAC ECR Ion Sources,” *Proc. 24th Int. Workshop ECR Ion Sources*, vol. ECRIS2020, p. 3 pages, 0.783 MB, 2022, doi: 10.18429/JACOW-ECRIS2020-WEYZO01.
- [56] B. Isherwood and G. Machicoane, “The Relationship Between the Diffusion of Hot Electrons, Plasma Stability, and ECR Ion Source Performance,” *Proc. 24th Int. Workshop ECR Ion Sources*, vol. ECRIS2020, p. 5 pages, 3.740 MB, 2022, doi: 10.18429/JACOW-ECRIS2020-MOYZO03.
- [57] A. W. Chao and M. Tigner, Eds., *Handbook of accelerator physics and engineering*. River Edge, N.J: World Scientific, 1999.
- [58] C. Qian *et al.*, “LECR5 Development and Status Report,” *Proc. 24th Int. Workshop ECR Ion Sources*, vol. ECRIS2020, p. 4 pages, 1.186 MB, 2022, doi: 10.18429/JACOW-ECRIS2020-MOWZO02.
- [59] H. Wiedemann, *Particle Accelerator Physics*, 4th ed. in Graduate texts in Physics. Cham,: Springer, 2015. doi: 10.1007/978-3-319-18317-6.
- [60] R. Taylor, E. Benedetto, M. Sapinski, and J. Pasternak, “Slow extraction modelling for NIMMS hadron therapy synchrotrons,” *J. Phys. Conf. Ser.*, vol. 2420, no. 1, p. 012101, Jan. 2023, doi: 10.1088/1742-6596/2420/1/012101.
- [61] Yoshiyuki I., “Review of Medical Accelerator Development for Carbon-Ion Radiotherapy in Celebration of the 30th Anniversary of HIMAC,” *J. Part. Accel. Soc. Jpn.*, July 2025, doi: 10.50868/pasj.22.2_110.
- [62] Y. Matsuya *et al.*, “Track-structure modes in particle and heavy ion transport code system (PHITS): application to radiobiological research,” *Int. J. Radiat. Biol.*, vol. 98, no. 2, pp. 148–157, Feb. 2022, doi: 10.1080/09553002.2022.2013572.
- [63] L. Hetrick, J. Douglas, and D. Poudel, “Practical overview of the ICRP Publication 145 phantoms for use with MCNP,” *Radiat. Prot. Dosimetry*, vol. 199, no. 19, pp. 2328–2337, Nov. 2023, doi: 10.1093/rpd/ncad233.
- [64] C. H. Kim *et al.*, “ICRP Publication 145: Adult Mesh-Type Reference Computational Phantoms,” *Ann. ICRP*, vol. 49, no. 3, pp. 13–201, Oct. 2020, doi: 10.1177/0146645319893605.
- [65] K. Sato, T. Furuta, D. Satoh, and S. Tsuda, “Construction of new polygon mesh-type phantoms based on adult Japanese voxel phantoms,” *PLOS ONE*, vol. 19, no. 10, p. e0309753, Oct. 2024, doi: 10.1371/journal.pone.0309753.
- [66] V. Zaichick and S. Zaichick, “Distinguishing malignant from benign prostate using content of 17 chemical elements in prostatic tissue,” *Integr. Cancer Sci. Ther.*, vol. 3, no. 5, 2016, doi: 10.15761/ICST.1000208.
- [67] A. Kitagawa, T. Fujita, M. Muramatsu, S. Biri, and A. G. Drentje, “Review on heavy ion radiotherapy facilities and related ion sources (invited),” *Rev. Sci. Instrum.*, vol. 81, no. 2, p. 02B909, Feb. 2010, doi: 10.1063/1.3268510.
- [68] J. Kim, J. M. Park, and H.-G. Wu, “Carbon Ion Therapy: A Review of an Advanced Technology,” *Prog. Med. Phys.*, vol. 31, no. 3, pp. 71–80, Sept. 2020, doi: 10.14316/pmp.2020.31.3.71.
- [69] Y.-M. Kang *et al.*, “The clinical relative biological effectiveness and prostate-specific antigen kinetics of carbon-ion radiotherapy in low-risk prostate cancer,” *Cancer Med.*, vol. 12, no. 2, pp. 1540–1551, 2023, doi: 10.1002/cam4.5045.



- [70] A. Parisi, K. M. Furutani, and C. J. Beltran, “Variation of the relative biological effectiveness in the penumbra of ion therapy beams estimated using different microdosimetric approaches,” *Phys. Imaging Radiat. Oncol.*, vol. 29, p. 100564, Feb. 2024, doi: 10.1016/j.phro.2024.100564.
- [71] W. Wang *et al.*, “RBE-weighted dose conversions for carbon ionradiotherapy between microdosimetric kinetic model and local effect model for the targets and organs at risk in prostate carcinoma,” *Radiother. Oncol.*, vol. 144, pp. 30–36, Mar. 2020, doi: 10.1016/j.radonc.2019.10.005.
- [72] G. Patel, A. Mandal, R. Shende, and A. Bharati, “Radiotherapy plan evaluation indices: A dosimetrical suitability check,” *J. Cancer Res. Ther.*, vol. 17, no. 2, pp. 455–462, Apr. 2021, doi: 10.4103/jcrt.JCRT_417_19.
- [73] “The International Commission on Radiation Units and Measurements,” *J. ICRU*, vol. 10, no. 1, p. NP.2-NP, Apr. 2010, doi: 10.1093/jicru/ndq001.
- [74] Faculty of Physics, West University of Timisoara, I. Gazsi, L. G. Marcu, and Faculty of Physics, West University of Timisoara, “Dosimetric Evaluation of the Benefits of Intensity Modulated Techniques in Cervical Cancer Radiotherapy,” *Romanian J. Phys.*, vol. 68, no. 7–8, pp. 702–702, Sept. 2023, doi: 10.59277/RomJPhys.2023.68.702.
- [75] S. Bisello *et al.*, “Dose–Volume Constraints fOr oRganS At risk In Radiotherapy (CORSAIR): An ‘All-in-One’ Multicenter–Multidisciplinary Practical Summary,” *Curr. Oncol.*, vol. 29, no. 10, pp. 7021–7050, Sept. 2022, doi: 10.3390/currenocol29100552.
- [76] Y. Takakusagi *et al.*, “Five-year clinical outcomes of scanning carbon-ion radiotherapy for prostate cancer,” *PLOS ONE*, vol. 19, no. 3, p. e0290617, Mar. 2024, doi: 10.1371/journal.pone.0290617.

